CNTA · Centessa Pharmaceuticals plc
Market Cap
$6.27B
Shares
154.73M
No Price Data
No daily price data is available for this stock yet. Data syncs automatically from Yahoo Finance.
Up next
filed May 5, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$250.64M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+15.4%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Limited
Momentum
Limited
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Limited
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
Not enough data for a confident read.
Momentum
relative strength
Not enough data for a confident read.
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+9% holders QoQ · +48 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.04% of float · ▼ -37.4% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
162 holders — near 3-yr high, broad support
Fundamentals
EPS growth
+29%
Y/Y
Free cash flow
$-194.2M
Balance sheet
$48.8M
net debt
Quant / Vol
risk profile
Not enough data for a confident read.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNTA
this stock
Centessa Pharmaceuticals plc
|
$6.27B | — | — | — | 1.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.40B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.60B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events